Literature DB >> 8605439

Ancrod for coronary angioplasty.

A J Pothoulakis1, S K Neerukonda, G Ansel, R D Jantz.   

Abstract

Anticoagulation in the form of intravenous heparin is used after coronary angioplasty to prevent thrombosis. Ancrod, a rapid-acting defibrinogenating agent, has been used in various clinical settings that require anticoagulation. We present the use of ancrod after percutaneous transluminal coronary angioplasty in a patients with heparin-induced thrombopathia.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8605439      PMCID： PMC325287     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


  17 in total

1.  Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172.

Authors:  B H Chong; F Ismail; J Cade; A S Gallus; S Gordon; C N Chesterman
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

2.  Selective thrombin inhibitors: the next generation of anticoagulants.

Authors:  E Deutsch; A K Rao; R W Colman
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

Review 3.  Low molecular weight heparin treatment of venous thromboembolism.

Authors:  R D Hull; G F Pineo
Journal:  Prog Cardiovasc Dis       Date:  1994 Sep-Oct       Impact factor: 8.194

4.  Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia.

Authors:  C Demers; J S Ginsberg; P Brill-Edwards; A Panju; T E Warkentin; D R Anderson; C Turner; J G Kelton
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

5.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.

Authors:  A Leizorovicz; G Simonneau; H Decousus; J P Boissel
Journal:  BMJ       Date:  1994-07-30

6.  Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass.

Authors:  R L Singer; J D Mannion; T L Bauer; F R Armenti; R N Edie
Journal:  Chest       Date:  1993-11       Impact factor: 9.410

Review 7.  Leeches to hirulogs and other thrombin-directed antithrombotics.

Authors:  J W Fenton
Journal:  Hematol Oncol Clin North Am       Date:  1992-10       Impact factor: 3.722

8.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

Authors:  E M Antman
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

9.  Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

Authors:  K L Neuhaus; R von Essen; U Tebbe; A Jessel; H Heinrichs; W Mäurer; W Döring; D Harmjanz; V Kötter; E Kalhammer
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

Review 10.  Heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.